Synergistic anticancer effect of CDRI-08 and Abiraterone acetate against castration resistant prostate cancer targeting PI3K/Akt pathway

Articles in Press

Document Type : Original Article

Authors

Department of Biomedical Sciences, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India

10.22038/ijbms.2025.85330.18441

Abstract

Objective(s): There is a considerable interest in combination therapy targeting the complex interlinked pathways in prostate cancer due to the development of drug resistance with monotherapies. A standardized fraction of Bacopa monnieri CDRI-08 was developed and patented by the Central Drug Research Institute (CDRI), Lucknow, for the treatment of neurodegenerative diseases. Recent studies with the plant and its phytocompounds have shown effective anticancer and antioxidant activity. Therefore, in the current research, the combined effect of Abiraterone acetate (AA) and CDRI-08 was studied in androgen-independent prostate cancer cells in vitro.
Materials and Methods: Initially, the in vivo toxicity of CDRI-08 was studied in zebrafish embryos. In vitro individual cytotoxicity and the synergistic effect of AA and CDRI-08 were studied in PC3 cell lines with and without growth factors. Nuclear staining with AO/EB and western blotting were performed to analyse apoptotic cell death and changes in protein expression of p-AKT and Casp3 in individual and combination-treated cells.
Results: CDRI-08 has shown no toxicity and teratogenicity in zebrafish embryos. AA and CDRI-08 have shown dose-dependent cytotoxic effects in PC3 cell lines with and without growth factors. Synergism was observed with different concentration ratios of AA and CDRI-08 with and without growth factors, with a good combination index (CI). Apoptosis was observed in individual and combination treated cells with an increase in Casp3 and simultaneous decrease in p-AKT expression levels.
Conclusion: The study confirms the synergistic effect of CDRI-08 and AA at a lower dose, targeting the tyrosine kinase and androgen receptor pathways.

Keywords

Main Subjects

References

1. Rawla P. Epidemiology of prostate cancer. World J Oncol 2019;10: 63-89.
2. Caffo O, Veccia A, Kinspergher S, Maines F. Abiraterone acetate and its use in the treatment of metastatic prostate cancer: A review. Future Oncol 2018;14: 431-442.
3. Saad F, Bögemann M, Suzuki K, Shore N. Treatment of nonmetastatic castration-resistant prostate cancer: Focus on second-generation androgen receptor inhibitors. Prosta Cancer Prostatic Dis 2021; 24: 323-334.
4. Armstrong CM, Gao AC. Dysregulated androgen synthesis and anti-androgen resistance in advanced prostate cancer. Am J Clin Exp Urol 2021; 9: 292-300.
5. H. Bolek, Yazgan SC, Yekedüz E, Kaymakcalan MD, McKay RR, Gillessen S,  et al. Androgen receptor pathway inhibitors and drug–drug interactions in prostate cancer. ESMO Open 2024; 9: 1-16.
6. Tortorella E, Giantulli S, Sciarra A, Silvestri I. AR and PI3K/AKT in prostate cancer: A tale of two interconnected pathways. Int J Mol Sci 2023; 24: 2046-2064.
7. Choudhury AD. PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications. Prostate 2022; 82: S60-S72.
8. Vakil V, Trappe W. Drug combinations: Mathematical modeling and networking methods. Pharmaceutics 2019; 11: 208-239.
9. Milczarek M, Pogorzelska A, Wiktorska K. Synergistic interaction between 5-FU and an analog of sulforaphane-2-oxohexyl isothiocyanate-in an in vitro colon cancer model. Molecules 2021; 26: 3019-3033.
10. Shore N, Mellado B, Shah S, Hauke R, Costin D, Adra N, et al. A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2023; 21: 278-285.
11. Zhou Q, Fang G, Pang Y, Wang X. Combination of kaempferol and docetaxel induces autophagy in prostate cancer cells in vitro and in vivo. Int J Mol Sci 2023; 24: 14519-14533.
12. Raith F, O’Donovan DH, Lemos C, Politz O, Haendler B. Addressing the reciprocal crosstalk between the AR and the PI3K/AKT/mTOR signaling pathways for prostate cancer treatment. Int J Mol Sci 2023; 24: 2289-2318.
13. Jeyasri R, Muthuramalingam P, Suba V, Ramesh M, Chen JT. Bacopa monnieri and their bioactive compounds inferred multi-target treatment strategy for neurological diseases: A cheminformatics and system pharmacology approach. Biomolecules 2020; 10: 536-555.
14. McPhee GM, Downey LA, Wesnes KA, Stough C. The neurocognitive effects of Bacopa monnieri and cognitive training on markers of brain microstructure in healthy older adults. Front Aging Neurosci 2021; 13: 63810-63823.
15. Vinod A, Sathianarayanan S, Babu A, Sadanandan P, K V A, Venkidasamy B. Bacopa monnieri for Disorders Affecting Brain: Current Perspectives. Curr Top Med Chem 2022; 22: 1909-1929.
16. Patel SK, Singh S, Singh SK. Standardized extract of Bacopa monnieri (CDRI-08): Effect on germ cell dynamics and possible mechanisms of its beneficial action on spermatogenesis and sperm quality in male mice. Biochem Biophys Res Commun 2017; 494: 34-41.
17. Ma J, Motsinger-Reif A. Current methods for quantifying drug synergism. Proteom Bioinform 2019; 1: 43-48.
18. Mendis J, Tennakoon T, Jayasinghe C. Zebrafish embryo toxicity of a binary mixture of pyrethroid insecticides: d-tetramethrin and cyphenothrin. J Toxicol 2018; 2018: 1-8.
19. Ghasemi M, Turnbull T, Sebastian S, Kempson I. The MTT assay: Utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis. Int J Mol Sci 2021; 22: 12827-12857.
20. Demidenko E, Miller TW. Statistical determination of synergy based on Bliss definition of drugs independence. PLoS One 2019; 14: e0224137-0224159.
21. Biba V, Kunjiraman S, Rajam SSN, Anil S. The apoptotic properties of leaf extracts of Simarouba glauca against human leukemic cancer cells. Asian Pac J Cancer Prev 2021; 22: 1305-1312.
22. Soylu H, Kırca M, Avcı S, Ozpolat B, Ustunel I. Antiandrogen abiraterone and docetaxel treatments affect Notch1, Jagged1 and Hes1 expressions in metastatic prostate cancer cells. Exp Mol Pathol 2021; 119: 104607.
23. Sharma N, Raut PW, Baruah MM, Sharma A. Combination of quercetin and 2-methoxyestradiol inhibits epithelial-mesenchymal transition in PC-3 cell line via Wnt signaling pathway. Future Sci OA 2021; 7: Fso747-759.
24. Bush KT, Boichard A, Tsigelny IF. In vitro elucidation of drug combination synergy in treatment of pancreatic ductal adenocarcinoma. Anticancer Res 2018; 38: 1967-1977.
25. Cai M, Song XL, Li XA, Chen M, Guo J, Yang DH, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat 2023; 68: 100962-100973.
26. Nevedomskaya E, Baumgart SJ, Haendler B. Recent advances in prostate cancer treatment and drug discovery. Int J Mol Sci 2018;19: 1359-1384.
27. Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, et al. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. Front Endocrinol 2022; 13: 1006101-1006116.
28. Prasathkumar M, Anisha S, Dhrisya C, Becky R, Sadhasivam S. Therapeutic and pharmacological efficacy of selective Indian medicinal plants–A review. Phytomedicine Plus 2021; 1: 100029-100057.
29. Khatoon E, Banik K, Harsha C, Sailo BL, Thakur KK, Khwairakpam AD, et al. Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives. Semin Cancer Biol 2022; 80: 306-39.
30. El Moussaoui A, Bourhia M, Jawhari FZ, Mechchate H, Slighoua M, Bari A, et al. Phytochemical identification, acute, and sub-acute oral toxicity studies of the foliar extract of Withania frutescens. Molecules 2020; 25: 4528-4538.
31. Chahardehi AM, Arsad H, Lim V. Zebrafish as a successful animal model for screening toxicity of medicinal plants. Plants  2020; 9: 1345-1378.
32. Ota H, Sato H, Mizumoto S, Wakai K, Yoneda K, Yamamoto K, et al. Switching mechanism from AR to EGFR signaling via 3-O-sulfated heparan sulfate in castration-resistant prostate cancer. Sci Rep 2023; 13: 11618-11634.
33. Lin SR, Yeh HL, Liu YN. Interplay of epidermal growth factor receptor and signal transducer and activator of transcription 3 in prostate cancer: Beyond androgen receptor transactivation. Cancers 2021; 13: 3452-3472.
34. Sheng Z, Sun Y, Yin Z, Tang K, Cao Z. Advances in computational approaches in identifying synergistic drug combinations. Brief Bioinform 2018; 19: 1172-1182.
35. Liu Q, Yin X, Languino LR, Altieri DC. Evaluation of drug combination effect using a bliss independence dose–response surface model. Stat Biopharm Res 2018; 10:112-122.
36. Gasmi A, Roubaud G, Dariane C, Barret E, Beauval J-B, Brureau L, et al. Overview of the development and use of akt inhibitors in prostate cancer. J Clin Med 2022; 11: 160-170.
37. Gano CA, Fatima S, Failes TW, Arndt GM, Sajinovic M, Mahns D, et al. Anti-cancer potential of synergistic phytochemical combinations is influenced by the genetic profile of prostate cancer cell lines. Front Nutr 2023; 10: 1119274-1119286.
38. Morana O, Wood W, Gregory CD. The apoptosis paradox in cancer. Int J Mol Sci 2022; 23: 1328-1347.
39. Lichan C, Yanyun Z, Shu-Feng Z. Role of Apoptosis in Cancer Resistance to Chemotherapy. In: Yusuf T, editor. Current Understanding of Apoptosis. Rijeka: IntechOpen; 2018. p. Ch. 7.
40. Liu K, Liu PC, Liu R, Wu X. Dual AO/EB staining to detect apoptosis in osteosarcoma cells compared with flow cytometry. Med Sci Monit Basic Res 2015; 21: 15-20.
41. Wal P, Verma N, Saxena B, Singh D, Wal A, Ved A, et al. Detailed analysis of the anti-inflammatory, anti-oxidant, and neuroprotective effects of the potent phytochemical bacoside A. Nat Prod J 2024; 14: 49-55.
42. Jonnalagadda B, Arockiasamy S, Vetrivel U, P AA. In silico docking of phytocompounds to identify potent inhibitors of signaling pathways involved in prostate cancer. J Biomol Struct Dyn 2021; 39: 5182-5208.
43. Sugawara T, Nevedomskaya E, Heller S, Böhme A, Lesche R, von Ahsen O, et al. Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis. Mol Oncol 2024; 18: 726-742.
44. Pilling AB, Hwang C. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide. Prostate 2019; 79: 1347-1359.
45. Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis 2020; 11: 797-809.
46. Lim W, Park S, Bazer FW, Song G. Naringenin-induced apoptotic cell death in prostate cancer cells is mediated via the PI3K/AKT and MAPK signaling pathways. J Cell Biochem 2017; 118: 1118-1131.
47. Zhou M, Liu X, Li Z, Huang Q, Li F, Li CY. Caspase-3 regulates the migration, invasion and metastasis of colon cancer cells. Int J Cancer 2018; 143: 921-930.
48. Butler DE, Marlein C, Walker HF, Frame FM, Mann VM, Simms MS, et al. Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer. Oncotarget 2017; 8: 56698-56713.
49. Toren P, Kim S, Cordonnier T, Crafter C, Davies BR, Fazli L, et al. Combination AZD5363 with enzalutamide significantly delays enzalutamide-resistant prostate cancer in preclinical models. Eur Urol 2015; 67: 986-990.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 16 April 2025

Files

Share

How to cite

Statistics